Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

19

Revenue 2017

Keytruda

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Keytruda was produced by Merck & Co..

LifeArc takes $30m equity stake in Kymab, gains access to antibody tech

LifeArc takes $30m equity stake in Kymab, gains access to antibody tech Keytruda windfall helps research charity invest. Kymab's HQ at the Babraham campus, Cambridge, UK. ... The new investment has been made possible by a big step forward for LifeArc - a $1.29bn royalty deal based on its role in developing immuno-oncology

Merck says it has plenty in the pipe beyond Keytruda

Merck says it has plenty in the pipe beyond Keytruda Merck &Co’s first investor day for five years had three major takeaway messages: Keytruda will continue to drive growth for the foreseeable future, the pipeline has plenty of breadth to ... What lies beyond Keytruda (pembrolizumab) for Merck has been a

25 Women Leaders in UK Healthcare

25 Women Leaders in UK Healthcare its role in developing immuno-oncology blockbuster Keytruda. ... The coming Keytruda windfall will also allow the charity to set up a stand-alone venture capital division, with which it could seed funding and help promote research in key areas.

Merck & Co adds to immunotherapy again with $773m Tilos buy

Merck & Co adds to immunotherapy again with $773m Tilos buy Keytruda. It adds to a string of recent mid-sized purchases in the field by the company, including OncoEthix in December,   ImmuneDesign in February and Peloton last month, as the company

Keytruda begins pursuit of rivals in small cell lung cancer

Keytruda begins pursuit of rivals in small cell lung cancer Set for competition with Opdivo. Merck &Co. has gained approval for Keytruda for use in third line treatment of small cell lung cancer (SCLC). ... Merck is already exploring Keytruda’s use in combination with chemotherapy in a phase 3 KEYNOTE-604 study.

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics